
Opinion|Videos|September 18, 2024
Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What additional factors do you consider when determining the most effective sequence of these therapies (FTD/TPI plus bevacizumab, fruquintinib, regorafenib)?
- What future research is needed to better understand the optimal sequencing of these therapies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP
4
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
5
















































